These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 31150699)

  • 21. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-tuberculous mycobacterial infections in psoriasis patients treated with biologics.
    Choi YM; Adelzadeh L; Wu JJ
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e99-e101. PubMed ID: 26388307
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of severe psoriasis in children: recommendations of an Italian expert group.
    Fortina AB; Bardazzi F; Berti S; Carnevale C; Di Lernia V; El Hachem M; Neri I; Gelmetti CM; Lora V; Mazzatenta C; Milioto M; Moretta G; Patrizi A; Peris K; Villani A
    Eur J Pediatr; 2017 Oct; 176(10):1339-1354. PubMed ID: 28836064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reducing patient copayment levels for topical and systemic treatments in plaque psoriasis as a case for evidence-based, sustainable pharmaceutical policy change in Greece.
    Souliotis K; Golna C; Kani C; Litsa P
    J Med Econ; 2016 Nov; 19(11):1021-1026. PubMed ID: 27207488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis.
    Plachouri KM; Georgiou S
    Int J Dermatol; 2019 Sep; 58(9):1008-1013. PubMed ID: 30891751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
    Gottlieb AB; Blauvelt A; Thaçi D; Leonardi CL; Poulin Y; Drew J; Peterson L; Arendt C; Burge D; Reich K
    J Am Acad Dermatol; 2018 Aug; 79(2):302-314.e6. PubMed ID: 29660421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching biologics in severe pediatric psoriasis: a retrospective analysis.
    Ramos Pinheiro R; Diamantino F; Cabete J; Brasileiro A; Baptista J; Lopes MJP
    Int J Dermatol; 2017 Dec; 56(12):1461-1464. PubMed ID: 28960270
    [No Abstract]   [Full Text] [Related]  

  • 30. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.
    Gaspari AA; Tyring S
    Dermatol Ther; 2015; 28(4):179-93. PubMed ID: 26201310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biologics. New drugs, new adverse reactions].
    Prinz JC
    Hautarzt; 2010 Aug; 61(8):668-75. PubMed ID: 20585746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practical Strategies for Optimizing Management of Psoriasis.
    Wu JJ; Armstrong AW; Gordon KB; Menter MA
    Semin Cutan Med Surg; 2018 Feb; 37(2S):S52-S55. PubMed ID: 29614139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of biologics and other systemic agents in the treatment of pediatric psoriasis.
    Wright NA; Piggott CD; Eichenfield LF
    Semin Cutan Med Surg; 2010 Mar; 29(1):20-7. PubMed ID: 20430304
    [No Abstract]   [Full Text] [Related]  

  • 34. The management of moderate-to-severe chronic plaque psoriasis.
    Tonini A; Panduri S; D' Erme AM; Papadia F; Romanelli M; Krueger JG; Chiricozzi A
    G Ital Dermatol Venereol; 2017 Oct; 152(5):447-457. PubMed ID: 28534602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic Therapy in Psoriasis: Safety Profile.
    Campanati A; Ganzetti G; Giuliodori K; Molinelli E; Offidani A
    Curr Drug Saf; 2016; 11(1):4-11. PubMed ID: 26463245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
    Menter A; Strober BE; Kaplan DH; Kivelevitch D; Prater EF; Stoff B; Armstrong AW; Connor C; Cordoro KM; Davis DMR; Elewski BE; Gelfand JM; Gordon KB; Gottlieb AB; Kavanaugh A; Kiselica M; Korman NJ; Kroshinsky D; Lebwohl M; Leonardi CL; Lichten J; Lim HW; Mehta NN; Paller AS; Parra SL; Pathy AL; Rupani RN; Siegel M; Wong EB; Wu JJ; Hariharan V; Elmets CA
    J Am Acad Dermatol; 2019 Apr; 80(4):1029-1072. PubMed ID: 30772098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
    JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Could anti IL12/23 therapy replace anti-TNF biologics?
    Ionescu MA; Lipozencić J
    Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse Reactions to Biologics in Psoriasis.
    Lockwood SJ; Prens LM; Kimball AB
    Curr Probl Dermatol; 2018; 53():1-14. PubMed ID: 29131033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.